INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS

• US 20100278898A1
• Filed: 04/16/2010
• Published: 11/04/2010
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: HUGHES, Patrick M., BURKE, James A., ROBINSON, Michael R.
• Granted Patent: US 8,673,341 B2
• Time in Patent Office: Days
• US Class Current: 424/428
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/204 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm'"'"'s Canal.

Claims

1. A method of treating an ocular condition, comprising the step of placing a biodegradable intraocular implant in an eye of the patient in need of said treatment, said implant comprising a prostamide associated with a biodegradable polymer matrix that releases an amount of a prostamide effective to prevent or reduce a symptom of the ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm'"'"'s Canal.

2. The method of claim 1 wherein and said implant is placed in an intracameral location to dilate the vessels in the episcleral and conjunctival venous plexus.

3. The method of claim 1 wherein and said implant is placed at the 6:

00 O'"'"'clock position to thereby well-mix the prostamide throughout the anterior segment through the convection currents.

4. The method of claim 1, wherein the implant is placed in the anterior chamber of the eye.

5. The method of claim 1, wherein the implant is placed in the iridocorneal angle of the eye.

6. The method of claim 1, wherein the implant is placed in the eye using an ocular implant delivery assembly comprising:

(a) a cannula having an outer wall, a proximal end, a proximal end opening, a distal end, a distal end opening, and a lumen extending through the cannula;

(b) an ocular implant sized and structured for implantation in an eye, the ocular implant being located in the lumen; and

(c) a cap having a closed distal end, being in contact with the outer wall of the cannula, and covering the distal end and the distal end opening of the cannula, the cap being structured to allow the distal end and the distal end opening of the cannula to pass through the cap as the cannula is passed into an eye.

7. The method of claim 1 wherein said bimatoprost is a compound having the formula (I).

8. The method of claim 8 wherein the prostamide has the following formula (II)

9. The method of claim 8, wherein the prostamide comprises bimatoprost, salts thereof, and mixtures thereof.

10. The method of claim 9 wherein said IOP is reduced at least-60% from baseline.

11. The method of claim 9 wherein said IOP is reduced in an amount greater then obtained with topical bimatoprost.

12. The method of claim 11, wherein the release of the prostamide is effective for at least two weeks after placement in the eye

13. A method of lowering the intraocular pressure in the eye of a patient, by dilating the outflow channels of the eye emanating from the Schlemm'"'"'s Canal with a prostamide.

14. A method of treating an ocular condition, comprising the step of placing a biodegradable intraocular implant in an eye of the patient in need of said treatment, said implant comprising a prostaglandin or prodrug thereof associated with a biodegradable polymer matrix that releases an amount of prostaglandin or prodrug thereof effective to prevent or reduce a symptom of the ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm'"'"'s Canal.

15. The method of claim 14, wherein the prostaglandin or prodrug thereof comprises latanoprost.

16. A method of lowering the intraocular pressure in the eye of a patient, by dilating the outflow channels of the eye emanating from the Schlemm'"'"'s Canal with a drug that is effective to lower elevated intraocular pressure in the eye of a patient.